Literature DB >> 32274668

Androgen Receptor Stimulates Hexokinase 2 and Induces Glycolysis by PKA/CREB Signaling in Hepatocellular Carcinoma.

R F Sun1, C Y Zhao2, S Chen2, W Yu2, M M Zhou2, C R Gao3.   

Abstract

BACKGROUND: Hepatocellular carcinoma (HCC) escapes growth inhibition by upregulating hexokinase 2 (HK2); however, the mechanism by which tumor cells upregulate HK2 remains unclear. AIM: We aimed to investigate the role of androgen receptor (AR) signalling in promoting HK2 expression in HCC.
METHODS: The expressions of AR and HK2 in HCC tissues were analyzed by immunohistochemistry. Cell proliferation was determined using the CCK-8 assay, and the molecular mechanism of AR in the regulation of HK2 was evaluated by immunoblotting and luciferase assays.
RESULTS: AR expression is positively correlated with HK2 staining by an immunohistochemical analysis. The manipulation of AR expression changed HK2 expression and glycolysis. AR signaling promoted the growth of HCC by enhancing HK2-mediated glycolysis. Moreover, AR stimulated HK2 levels and glycolysis by potentiating protein kinase A/cyclic adenosine monophosphate response element-binding (CREB) protein signaling. CREB silencing decreased HK2 expression and inhibited AR-mediated HCC glycolysis. AR affected the sensitivity of HCC cells to glycolysis inhibitors by regulating downstream phosphorylated (p)-CREB.
CONCLUSIONS: These results indicate that AR at least partially induced glycolysis via p-CREB regulation of HK2 in HCC cells. Thus, this pathway should be considered for the design of novel therapeutic methods to target AR-overexpressing HCC.

Entities:  

Keywords:  Androgen receptor; CREB; Glycolysis; Hexokinase 2; Liver cancer; Metabolism

Year:  2020        PMID: 32274668     DOI: 10.1007/s10620-020-06229-y

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  4 in total

Review 1.  Recent advances in the molecular mechanism of sex disparity in hepatocellular carcinoma.

Authors:  Yanmeng Li; Anjian Xu; Siyu Jia; Jian Huang
Journal:  Oncol Lett       Date:  2019-03-08       Impact factor: 2.967

2.  Novel therapy for liver cancer: direct intraarterial injection of a potent inhibitor of ATP production.

Authors:  Jean-Francois H Geschwind; Young H Ko; Michael S Torbenson; Carolyn Magee; Peter L Pedersen
Journal:  Cancer Res       Date:  2002-07-15       Impact factor: 12.701

3.  Androgens stimulate hypoxia-inducible factor 1 activation via autocrine loop of tyrosine kinase receptor/phosphatidylinositol 3'-kinase/protein kinase B in prostate cancer cells.

Authors:  Nicola J Mabjeesh; Margaret T Willard; Carrie E Frederickson; Hua Zhong; Jonathan W Simons
Journal:  Clin Cancer Res       Date:  2003-07       Impact factor: 12.531

4.  Tumor localization of 16beta-18F-fluoro-5alpha-dihydrotestosterone versus 18F-FDG in patients with progressive, metastatic prostate cancer.

Authors:  Steven M Larson; Michael Morris; Ilonka Gunther; Brad Beattie; John L Humm; Timothy A Akhurst; Ronald D Finn; Yusuf Erdi; Keith Pentlow; Jon Dyke; Olivia Squire; William Bornmann; Timothy McCarthy; Michael Welch; Howard Scher
Journal:  J Nucl Med       Date:  2004-03       Impact factor: 10.057

  4 in total
  5 in total

Review 1.  Metabolic changes during prostate cancer development and progression.

Authors:  Alicia-Marie K Beier; Martin Puhr; Matthias B Stope; Christian Thomas; Holger H H Erb
Journal:  J Cancer Res Clin Oncol       Date:  2022-09-23       Impact factor: 4.322

2.  Regulation of Gamma-Aminobutyric Acid Transaminase Expression and Its Clinical Significance in Hepatocellular Carcinoma.

Authors:  Xiaoqiang Gao; Xiaodong Jia; Moyan Xu; Jiao Xiang; Jin Lei; Yinyin Li; Yinying Lu; Shi Zuo
Journal:  Front Oncol       Date:  2022-06-24       Impact factor: 5.738

Review 3.  Emerging roles and the regulation of aerobic glycolysis in hepatocellular carcinoma.

Authors:  Jiao Feng; Jingjing Li; Liwei Wu; Qiang Yu; Jie Ji; Jianye Wu; Weiqi Dai; Chuanyong Guo
Journal:  J Exp Clin Cancer Res       Date:  2020-07-06

Review 4.  Emerging therapies for autosomal dominant polycystic kidney disease with a focus on cAMP signaling.

Authors:  Xia Zhou; Vicente E Torres
Journal:  Front Mol Biosci       Date:  2022-09-02

5.  MXD3 Promotes Obesity and the Androgen Receptor Signaling Pathway in Gender-Disparity Hepatocarcinogenesis.

Authors:  Yi-Wen Tsai; Kuo-Shyang Jeng; Mu-Kuang He; Yang-Wen Hsieh; Hsin-Hung Lai; Chi-Yu Lai; Chun-Chieh Huang; Chiung-Fang Chang; Chung-Tsui Huang; Guor Mour Her
Journal:  Cells       Date:  2021-12-06       Impact factor: 6.600

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.